« July 2007 | Main | November 2007 »
September
Advanced Modelling Methods For Health Economic Evaluation
Location: York (England), Sydney (Australia), Glasgow (Scotland)
Dates: 21-23 March, 23-25 July, and September (TBA)
This 3-day computer-based workshop is now being held in 3 locations:
- York, UK (March 21-23, 2007);
- Sydney Australia (July 23-25, 2007);
- Glasgow, Scotland (September 2007 — exact date to be determined)
This course is designed for participants who are familiar with economic evaluation and healthcare and who wish to learn how to use more modelling techniques. It is envisaged that participants will currently be undertaking modelling for health economic evaluation within pharmaceutical and medical device industries, consultancy, academia or health services. By the end of the course, participants will be able to:
- develop and populate a decision model;
- populate a Markov model with and without time-dependent probabilities;
- make a model probabilistic to reflect parameter uncertainty and to run Monte Carlo simulation;
- present the results of a probabilistic model using net monetary benefits and cost-effectiveness acceptability curves; and
- assess the expected value of perfect information.
The course will provide an introduction to decision models including decision trees and standard Markov models. Greater sophistication will be added as building blocks over the 3-day course. This will include adding time dependency to Markov models, making models probabilistic, populating decision models using regression models, presenting the results of probabilistic models and undertaking value of information analysis.
Instructors for the workshop include:
- Andrew Briggs & Elisabeth Fenwick from the University of Glasgow,
- Mark Sculpher and Karl Claxton from the University of York, UK, and
- Ron Goeree from PATH, McMaster University, Canada.
For further details regarding these workshops, you can access our full colour brochure on the PATH web-site: http://www.path-hta.ca/.
Note: Special discounts are available for private sector employees, so book early
If you would like to receive a copy of our full colour brochure, please e-mail: hendersc@mcmaster.ca with your full postal address.
For further information regarding these workshops please contact:
Christine Henderson at 1-905-523-7284, x5268 (hendersc@mcmaster.ca) or
Jan Watson at 1-905-523-7284, x6188 (watsonj@mcmaster.ca) or visit our
website and follow the links to “workshops”
September 1, 2007: Short Course
September
PhD in Pharmaceutical Outcomes Research and Policy: University of Washington, Department of Pharmacy
Location: Seattle, Washington, USA
Application Deadline: 15 January 2007
Date of Commencement: 26 September 2007
Type of Course: Full-time
Class size: Average size of class intake is 3-4
E-mail: penny@u.washington.edu
Website: http://depts.washington.edu/porpp/gradpage.html
Program Description: The University of Washington created the Pharmaceutical Outcomes Research and Policy Program (PORPP) in 1995 to consolidate and coordinate research and training efforts among a number of faculty. Program faculty and professional staff provide medical facilities, health insurance providers pharmaceutical and device companies and governmental agencies with analyses on the safety and cost-effectiveness of prescription drugs in order to achieve a better understanding of the risks and benefits of medical and pharmaceutical interventions. PORPP has helped the UW become a nationally recognized center for pharmacoepidemiology, pharmacoeconomics, and pharmaceutical policy research.
Pharmaceutical outcomes research employs economic and epidemiologic methods to evaluate clinical outcomes, morbidity, quality of life, and cost-effectiveness. The graduate program in pharmaceutical outcomes research and policy trains students in economic evaluation, pharmacoepidemiology, health services research, and pharmaceutical policy formulation and evaluation.
Career Opportunities
Graduate training leading to a degree in Pharmaceutical Sciences prepares students for career opportunities in:
- Teaching and research at colleges and universities.
- Safety and economic evaluation of products in the pharmaceutical, biotechnology and medical device industries.
- Policy analysis for professional associations, health care insurance providers, and governmental agencies.
- Management within hospitals, managed care organizations and programs concerned with reimbursement for pharmaceuticals and other medical technologies.